Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Clinical trial NCT04340843 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04340843
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Unresectable Primary Central Chondrosarcoma Metastatic Primary Central Chondrosarcoma Unresectable Primary Central Chondrosarcoma

Start date: 2020-09-08
Primary completion: 2024-02-22
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.